[Stock in Focus] Organoid Science Surges on President's 'Alternative Animal Testing' Pledge... Selected as Samsung's Future Growth Driver

Organoid Science is showing strong performance. Expectations for growth in the organoid (organ-like structure) market appear to be influencing the stock price. During his presidential campaign, President Lee Jaemyung pledged to enact a law promoting alternatives to animal testing, promising the development and standardization of alternative animal testing methods. Companies such as Samsung Biologics, JW Pharmaceutical, and Daewoong have entered the market.

As of 10:00 a.m. on June 26, Organoid Science was trading at 32,100 won, up 2,400 won (8.08%) from the previous trading day.

Founded in 2018, Organoid Science is developing treatments for intractable diseases using "organoid" technology, which recreates human organs by culturing stem cells in three dimensions. Organoids demonstrate exceptional regenerative capabilities when transplanted into damaged tissues. In addition to developing the regenerative therapy "ATORM," the company also provides the new material efficacy evaluation solution "ODISEI." Organoid Science was the first in Korea to obtain clinical approval for advanced regenerative medicine and is currently administering treatments to patients. Following its designation as a national advanced strategic technology in 2023, the company succeeded in a technology-special listing as a leading player in the organoid field.

Through organoids, which are 3D organ mimetics derived from stem cells, Organoid Science is developing innovative technologies that serve as alternatives to animal testing and overcome the limitations of existing treatments. IV Research analyzed, "If the phased replacement of animal testing currently being discussed by the U.S. Food and Drug Administration (FDA) proceeds, Organoid Science could benefit significantly," adding, "We expect rapid growth in performance as the ATORM-C-based regenerative therapy enters full-scale commercialization."

They further stated, "If the company's major pipelines achieve successful global technology exports, additional upside potential could be realized," and added, "Unlike many existing small- and mid-sized biotech firms that face significant funding risks, Organoid Science has secured the ability to self-finance through sales performance, which is a positive factor."

Discussions on the phased abolition of animal testing are underway in both the United States and Europe, and President Lee Jaemyung also pledged the development and standardization of alternative animal testing methods during his candidacy. On May 21, while still a presidential candidate, President Lee Jaemyung promised to develop and standardize alternative animal testing laws.

According to market research firm Research and Markets, the patient-derived organoid market was valued at $1 billion (about 1.3678 trillion won) last year and is projected to grow at an average annual rate of 22%, reaching $3.3 billion (about 4.5137 trillion won) by 2030.

According to industry sources, on June 19 (local time), Samsung Biologics announced the expansion of its clinical research organization (CRO) business at the world's largest bio exhibition, "2025 BIO International Convention (BIO USA)," held in Boston, USA. The company plans to create a clinical trial platform that can replace ethically controversial animal testing by utilizing organoids, which are "mini organ models" formed by aggregating and culturing stem cells or tissue-derived cells in three dimensions.

This method offers lower costs compared to traditional experimental methods while achieving a high patient similarity rate of up to 85%. Through this approach, Samsung Biologics aims to expand contact points with client companies at the early stages of drug discovery and strengthen the client "lock-in effect" by initiating collaborations from the earliest phases.